Compare Crispr Therapeutics AG (CRSP) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs United States Natural Gas Fund — how do they compare? Crispr Therapeutics AG trades at $53.26 (market cap $4.88B), while United States Natural Gas Fund trades at $11.05 (market cap $517.27M). The key difference: Crispr Therapeutics AG is far larger — about 9.4× United States Natural Gas Fund's market cap, and United States Natural Gas Fund is more actively traded (29,485,537 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and United States Natural Gas Fund for 22 Days on average.
| CRSP | UNG | |
|---|---|---|
Market Cap | $4.88B | $517.27M |
Volume | 2,861,747 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $74.92 | $16.90 |
52-Week Low | $44.34 | $9.63 |
Typical Hold Time | 77 Days | 22 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
UNG trades at $11.03, up 2.7% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported a net income of $65.15 million in 2024 with no revenue, while cash flow from operations was positive at $47.54 million. Recent news highlights natural gas price volatility driven by record U.S. production and geopolitical tensions in the Middle East.
The outlook is mixed: strong profitability and low debt support fundamentals, but zero revenue and negative net cash flow pose risks. Geopolitical events and weather-dependent demand create volatility, making the stock sensitive to energy market shifts. Analyst sentiment is cautiously optimistic given the bullish technical setup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
